142 related articles for article (PubMed ID: 12697859)
1. Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
Cappelletti V; Veneroni S; Coradini D; Oriana S; Tomasic G; Younes M; Daidone MG
J Natl Cancer Inst; 2003 Apr; 95(8):629-30. PubMed ID: 12697859
[No Abstract] [Full Text] [Related]
2. How is tamoxifen's action subverted?
Jordan VC
J Natl Cancer Inst; 2000 Jan; 92(2):92-4. PubMed ID: 10639501
[No Abstract] [Full Text] [Related]
3. Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
Foulkes WD; Goffin J; Brunet JS; Bégin LR; Wong N; Chappuis PO
J Natl Cancer Inst; 2002 Oct; 94(19):1504-6. PubMed ID: 12359859
[No Abstract] [Full Text] [Related]
4. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.
van der Flier S; Brinkman A; Look MP; Kok EM; Meijer-van Gelder ME; Klijn JG; Dorssers LC; Foekens JA
J Natl Cancer Inst; 2000 Jan; 92(2):120-7. PubMed ID: 10639513
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptors in BRCA1-mutant breast cancer: now you see them, now you don't.
Jordan VC
J Natl Cancer Inst; 2007 Nov; 99(22):1655-7. PubMed ID: 18000213
[No Abstract] [Full Text] [Related]
6. [Response to tamoxifen in estrogen receptor-positive cell line MCF-7 is independent of p53 expression].
Shtam TA; Pantina RA; Varfolomeeva EIu; Filatov MV
Vopr Onkol; 2007; 53(2):194-9. PubMed ID: 17663174
[TBL] [Abstract][Full Text] [Related]
7. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
Terakawa N
Oncology; 2000; 59 Suppl 1():3-4. PubMed ID: 11096349
[No Abstract] [Full Text] [Related]
8. Playing the old piano: another tune for endocrine therapy?
Hayes DF
J Natl Cancer Inst; 2003 Nov; 95(21):1565-7. PubMed ID: 14600082
[No Abstract] [Full Text] [Related]
9. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.
Brinkman A; van der Flier S; Kok EM; Dorssers LC
J Natl Cancer Inst; 2000 Jan; 92(2):112-20. PubMed ID: 10639512
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
Lippman SM; Brown PH
J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
[No Abstract] [Full Text] [Related]
11. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.
Osin P; Crook T; Powles T; Peto J; Gusterson B
Lancet; 1998 May; 351(9114):1487. PubMed ID: 9605807
[No Abstract] [Full Text] [Related]
12. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
[TBL] [Abstract][Full Text] [Related]
13. Re: Playing the old piano: another tune for endocrine therapy.
Koeberle D; Perey L; Thuerlimann B;
J Natl Cancer Inst; 2004 Apr; 96(7):555-6; author reply 556-7. PubMed ID: 15069120
[No Abstract] [Full Text] [Related]
14. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
15. MRP as a new predictive marker of tamoxifen efficiency in treatment of estrogen receptor-positive breast cancer.
Bogush TA; Dudko EA; Bogush EA; Tikhomirov MV; Yu Kirsanov V; Davydov MI
Dokl Biochem Biophys; 2010; 430():36-40. PubMed ID: 20380160
[No Abstract] [Full Text] [Related]
16. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
[TBL] [Abstract][Full Text] [Related]
18. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen for primary breast cancer prevention in BRCA heterozygotes.
Robson M
Eur J Cancer; 2002 Nov; 38 Suppl 6():S18-9. PubMed ID: 12409059
[No Abstract] [Full Text] [Related]
20. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
